## Skeptic's Contribution: Methodological Limitations Undermine SEA-AD Conclusions
### Primary Argument: Postmortem Confounds and Biological Validity Concerns
The SEA-AD dataset's reliance on postmortem brain tissue introduces systematic confounders that cannot be adequately controlled, fundamentally compromising the biological validity of disease-associated transcriptional signatures. Recent evidence demonstrates that postmortem interval (PMI) itself leads to loss of disease-specific transcriptional signatures in brain tissue (PMID: 40015966). This finding is critical: if PMI confounds obscure disease-specific signals, then observed differences between AD cases and controls may partially reflect tissue degradation artifacts rather than true pathophysiology. The effects of postmortem interval on biomolecule integrity in the brain extend beyond simple RNA degradation, affecting cellular pathways and gene networks in non-linear, tissue-specific ways (PMID: 25868148).
Furthermore, the assumption that transcriptional changes observed in end-stage disease reflect causative mechanisms rather than downstream consequences of neurodegeneration represents a fundamental logical fallacy. The brain's response to chronic neurodegeneration—including gliosis, metabolic stress, and cellular senescence—induces transcriptional programs that may be epiphenomena rather than drivers of pathology. Without temporal resolution or functional validation, distinguishing between causative and compensatory transcriptional changes remains methodologically impossible.
### Secondary Argument: Batch Effects and Cross-Platform Reproducibility
Single-cell RNA sequencing technologies exhibit substantial technical variance across platforms, batch effects, and preprocessing pipelines that complicate cross-study comparisons (PMID: 31024627). A multicenter benchmarking study demonstrated that different scRNA-seq technologies produce systematically divergent results when applied to identical reference samples, with inter-platform concordance often below acceptable thresholds for biological inference (PMID: 33349700). The SEA-AD dataset, while standardized internally, represents a single technological approach applied to a geographically restricted population. This creates what I term "institutional portability" problems—the dataset may precisely capture phenomena within its own technical framework but fail to generalize across the diverse methodological landscape of modern neuroscience.
### Tertiary Argument: Cell Type Annotation Subjectivity and Inter-Lab Reproducibility
Cell type annotation in single-cell datasets remains fundamentally subjective, relying on marker gene lists that vary across studies and laboratories. Recent work comparing brain cell type annotations across studies reveals substantial disagreement in cell type assignments, particularly for transitional states and rare populations (PMID: 39990500). The SEA-AD consortium's cell type taxonomy, while internally consistent, may not align with annotations from other major brain atlases, creating barriers to meta-analysis and cross-study validation.
### Confidence Assessment
**Confidence: 0.82**
These arguments rest on well-documented phenomena in the single-cell genomics literature, but I acknowledge several caveats: (1) the SEA-AD consortium has implemented rigorous QC protocols that may mitigate some PMI concerns; (2) cross-platform standardization efforts are ongoing; and (3) the dataset's scale provides statistical power to detect even subtle effects, partially compensating for signal-to-noise challenges. However, the fundamental issue—that postmortem transcriptional data cannot definitively establish causal disease mechanisms—remains unresolved by any current methodological approach.